Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/53823
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuthida Intarapheten_US
dc.contributor.authorNongyao Kasatpibalen_US
dc.contributor.authorSumalee Siriaunkgulen_US
dc.contributor.authorAnchalee Chandachamen_US
dc.contributor.authorKornkanok Sukpanen_US
dc.contributor.authorJayanton Patumanonden_US
dc.date.accessioned2018-09-04T09:58:52Z-
dc.date.available2018-09-04T09:58:52Z-
dc.date.issued2014-01-01en_US
dc.identifier.issn15251438en_US
dc.identifier.issn1048891Xen_US
dc.identifier.other2-s2.0-84893771109en_US
dc.identifier.other10.1097/IGC.0000000000000059en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84893771109&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/53823-
dc.description.abstractObjective: This study aimed to determine the clinicopathologic characteristics that affected the survival in patients with small cell neuroendocrine carcinoma of the uterine cervix (SNEC). Materials and Methods: All patients with SNEC treated at Chiang Mai University Hospital between January 1995 and October 2011 were retrospectively reviewed with histologic confirmation of SNEC diagnosis. The prognostic predictors for survival were assessed using competing risk regression analysis concerning the probabilities of competing events. Results: One hundred thirty histologically confirmed patients with SNEC met the study criteria. The median overall survival and median cancer-specific survival (CSS) for entire group were 47.8 and 58.1 months, respectively. Five-year CSS for patients with early-stage disease was 62.6% and for patients with advanced-stage disease was 18.1% (P < 0.001). Among the patients with surgically treated early-stage disease, those with adjuvant chemotherapy had a better 5-year survival rate than those with surgery alone, those with adjuvant radiotherapy, and those with adjuvant chemoradiation therapy (P = 0.041). In multivariable analyses, decreased survival in patients with early-stage disease was associated with age older than 60 years at diagnosis (hazards ratio [HR], 4.9; P = 0.007) and deep stromal invasion (HR, 2.9; P = 0.011). Among the patients with advanced-stage disease, decreased survival was associated with age at diagnosis (older than 60 years: HR, 9.9; P < 0.001 and younger than 45 years: HR, 3.4; P = 0.035) and International Federation of Gynecology and Obstetrics stage IV (HR, 7.4; P = 0.024). Conclusions: International Federation of Gynecology and Obstetrics stage, age at diagnosis, and deep stromal invasion were important prognostic factors for CSS in patients with SNEC. Adjuvant chemotherapy may provide survival benefits in surgically treated patients with early-stage SNEC. Copyright © 2014 by IGCS and ESGO.en_US
dc.subjectMedicineen_US
dc.titlePrognostic factors for small cell neuroendocrine carcinoma of the uterine cervix: An institutional experienceen_US
dc.typeJournalen_US
article.title.sourcetitleInternational Journal of Gynecological Canceren_US
article.volume24en_US
article.stream.affiliationsBoromarajonnani College of Nursingen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.